Logan Lutton

Part two focuses on the requirement that Part D sponsors must make enrollees aware of upcoming benefits.

American Indian and Alaska Native women also had higher comorbidities and less access to private insurance than White women.

How Long COVID-19 rates differ across the pre-delta, delta and omicron eras.

Dr. Charles C. Wykoff discusses how a one-time gene therapy could benefit patients with wet age-related macular degeneration.

Dr. Charles C. Wykoff discusses interim results from a phase 2 trial of a gene therapy to treat with patients with wet age-related macular degeneration.

Grandmother and great-grandmother Donna Osborne had recently finished radiation therapy when she won the prize.

: A Taiwanese study builds upon previous contradictory research exploring the link between breast cancer and acute myocardial infarction.

Here’s what you missed this week on Managed Healthcare Executive.

The St. Louis-based center will serve as a base where researchers and public health experts can fight the HIV epidemic together.

This is good news for developing an HIV vaccine because previous research had indicated it could take years for these antibodies to appear.

A breakdown of recent survey results revealing which benefits employers plan to keep and what they are looking to add in 2025.

Ohtuvayre - an inhaled bronchodilator with non-steroidal anti-inflammatory effects - is the first new mechanism in COPD approved in more than 20 years.

Previous acupuncture studies have focused on European and American women, but little was known about breast cancer patients in Asia.

The CMS released its projections earlier this month, saying healthcare spending will hit $7.7 trillion by 2032.

Women with HIV are more affected by stigma, gender inequality and socioeconomic status when compared to men with HIV.

EndeavorOTC costs $24.99 monthly or $129.99 annually.

A recent industry survey conducted by HealthEdge provides insight into how health insurance consumers in the United States feel about their current coverage.

The same is not true for Black women, who are 40% more likely to die from breast cancer than white women, suggesting other factors are to blame.

Even though value-based care has been talked about for a long time, it may not be the end.

In 2024, there have been two common health plan issues brought up by employers.

Type 2 diabetes patients ages 10 and up can now take Farxiga.

In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about how GLP-1 agonist drugs like Wegovy and Zepbound are changing the paradigm for weight loss.

In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about the issues insurers consider when providing coverage for GLP-1 drugs like Wegovy and Zepbound that can help patients lose weight.

Study results may change the understanding and treatment of hormone-based treatment of primary ovarian insufficiency based on genetics.

Elafibranor is the first new medicine approved for primary biliary cholangitis in nearly a decade.

Rytelo is the first and only telomerase inhibitor approved by the FDA and is expected to be available by the end of summer 2024.

Fears also extend to the future of Social Security, which may run out by 2036, according to the Social Security Office of Retirement and Disability Policy.

Three-quarters of disenrollments were due to procedural reasons such as incomplete applications, application errors and inaccurate contact information.

This is the first new recommendation from the American Academy of Pediatrics since the AIDS epidemic began in the 1980s.

Healthcare providers and community leaders won’t need a green thumb to implement these changes.